The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Novartis (I); Pfizer (I)
Other Relationship - ARIAD (I); Bristol-Myers Squibb (I); Celgene (I)
A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor.
 
Timothy Anthony Yap
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Clearbridge Biomedics; Vertex
Travel, Accommodations, Expenses - Janssen-Cilag; MSD Oncology; Vertex
 
Peter W. M. Johnson
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Pfizer; Takeda
Research Funding - Epizyme; Janssen
 
Jane Winter
No Relationships to Disclose
 
John Leonard
No Relationships to Disclose
 
Lisa Giulino-Roth
No Relationships to Disclose
 
Thierry Horner
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Kristen Radswillas
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Jennifer Carver
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Arindam Dhar
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline